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ABSTRACT
As cerebral toxoplasmosis is the most common cerebral focal lesion in AIDS patients, this study 
evaluated three PCR markers for diagnosis, since some limitations remain present, such as low para-
site levels in some clinical samples. The molecular markers were B22-B23 and Tg1-Tg2 (based on 
the B1 gene) and Tox4-Tox5 (non-coding fragment, repeated 200-300-fold). DNA samples from 102 
AIDS patients with previously known diagnosis were analyzed. The cerebral toxoplasmosis group 
was constituted of DNA extracted from the blood of 66 AIDS patients, which was collected before or 
until the third day of the therapy for toxoplasmosis. DNA from the blood of 36 AIDS patients with 
other neurologic opportunistic infections was used as control group. Sensitivities of B22-B23, Tg1-
Tg2, and Tox4-Tox5 markers were of 95.5%, 93.9%, and 89.3%, respectively. In the control group, the 
specifi cities were of 97.2% (B22-B23), 88.9% (Tg1-Tg2), and 91.7% (Tox4-Tox5). The association of 
at least two markers increased the PCR sensitivity and specifi city. The concordance index between 
two markers varied from 83.3% to 93.1%. These data demonstrated that all markers evaluated here 
were highly sensitive for T. gondii determination, although B22-B23 has been shown to be the best. 
The association of two markers increases PCR sensitivity, but the procedure was more expensive and 
time-consuming.
Keywords: AIDS, cerebral toxoplasmosis, molecular diagnosis, PCR markers.
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INTRODUCTION
Toxoplasma gondii is an intracellular proto-
zoan parasite that infects all mammalian cells. 
Human infection is generally innocuous and 
asymptomatic. During the chronic phase, the 
parasites persist encysted in the brain and in 
muscles, developing life-long protective im-
munity against re-infection.1-3 However, re-
infections are also possible, since different T. 
gondii genotypes have been found in the same 
patient.4, 5 
Although the infection in humans is 
usually asymptomatic, ocular and dissemi-
nated forms of toxoplasmosis have been 
reported in immunocompetent patients, 
especially in South America.6,7 Symptomatic 
forms are frequent when the primary infec-
tion occurs either during pregnancy, which 
can result in severe neonatal malformations 
and ocular complications in the fetus, or in 
the setting of an immunodeficiency, such 
as AIDS. Reactivation of latent infection in 
AIDS patients results more frequently in 
cerebral toxoplasmosis and is a life-threat-
ening condition without timely diagnosis 
and treatment.2,8 
Cerebral toxoplasmosis remains a preva-
lent disorder of the central nervous system 
in developed countries, particularly among 
severely immunosuppressed HIV-infected 
patients in the absence of antibiotic proph-
ylaxis.9 This situation is critical in most 
resource-limited settings, where highly ac-
tive antiretroviral therapy (HAART) is not 
available. In Brazil, a developing country 
with universal and free access to HAART, 
cerebral toxoplasmosis still accounts for 
high mortality and morbidity.10 
Although the definitive diagnosis of cer-
ebral toxoplasmosis requires demonstration 
of tachyzoites in brain biopsy or necropsy, 
in clinical practice, treatment is usually ini-
tiated upon a presumptive diagnosis, which 
is based on clinical and radiological features. 
In the last decade, significant improvement 
has been made with the introduction of mo-
lecular diagnosis. PCR in cerebral toxoplas-
mosis diagnosis has been shown to be an 
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important diagnostic tool.11-13 In parallel, several DNA 
targets were evaluated and have been used regularly in 
different laboratories to diagnose congenital, ocular, dis-
seminated or cerebral toxoplasmosis. Among them, two 
are more frequently used due to their greater sensitivity 
and specificity. One is the 529-bp sequence, which has 
200-300 copies in the genome of T. gondii.14 The other 
is the B1 gene, having 35 copies in the genome and con-
served in different parasite strains.15,16 The sensitivity 
and accuracy of the target 529-bp sequence, B1 gene, and 
the comparison of both were largely analyzed.12-14,17-20 The 
majority of these studies aiming to compare sensitivities 
of both DNA regions were conducted in European clini-
cal samples, but little research has been done on Brazil-
ian samples.21 These data, combined with certain limita-
tions in laboratorial practices, such as the low parasite 
levels in some clinical samples, lead us to compare two 
molecular markers directed at the B1 gene and the 529-
bp sequence for cerebral toxoplasmosis diagnosis. 
 
MATERIAL AND METHODS 
Patients and clinical samples
We analyzed 102 DNA samples of patients with laboratorial, 
clinical, and radiological diagnosis previously known. The 
cerebral toxoplasmosis group comprised by 66 AIDS pa-
tients with positive IgG antibodies anti T. gondii determined 
by indirect immunoﬂ uoresce reaction and clinical and ra-
diological features had DNA extracted from the blood. Case 
defi nition for toxoplasmosis included the following criteria: 
(i) progressive neurological defi cits; (ii) contrast-enhancing 
mass lesion(s) on computed tomography; (iii) successful re-
sponse within two weeks to specifi c treatment.10,22 The blood 
samples were collected before or until the third day of the 
specifi c therapy for toxoplasmosis.23 For the control group, 
DNA was extracted from the blood of 36 AIDS patients with 
negative IgG antibodies anti T. gondii (by indirect immun-
oﬂ uoresce reaction) and diagnosed with other neurologic 
opportunistic infections, including cryptococcal menin-
goencephalitis, progressive multifocal leukoencephalopathy, 
central nervous system tuberculosis, and HIV-associated 
cognitive motor disorder. The ethics committees of the in-
stitutions involved approved this study.
DNA puriﬁ cation
The DNA of blood samples was extracted using PureLink 
Genomic DNA Kits (Invitrogen) according to the manufac-
turer’s instructions. Previously, blood samples were centri-
fuged, washed with PBS at 2,500 g for 10 min, and the su-
pernatants with plasma were discarded. In order to lyse the 
erythrocytes, the packed cells were mixed with three times 
the volume of a buffer containing 150 mM ammonium 
chlorate, 1 mM potassium bicarbonate, 0.1 mM EDTA, pH 
7.3, incubated for 15 min at room temperature under mild 
shaking, and centrifuged for 10 min at 3,000 g. The blood 
pellets containing only nuclei cells were digested with pro-
teinase K (20 µg/mL) in 50 mM Tris-HCl, 25 mM EDTA, pH 
8.0, 2% sodium dodecyl sulfate and incubated for 30 min at 
56 °C. The DNA pellets were dissolved in ultra pure water. 
As a positive control, DNA was extracted from tachyzoite 
pellets using the same kit. DNA purity was determined by 
the ratio of O. D. at 260 and 280 nm in a NanoDrop ND100 
(Thermo Scientifi c).24 
PCR
Each reaction was performed by adding 5 µL of each DNA 
template and 25 pmol of each primer to a fi nal volume of 
25 µL. The amplifi cations were carried out with a kit pur-
chased from Promega (Go Taq Green Master Mix). The 
PCR mix (12.5 µL) was composed of 1 unit of Taq DNA 
polymerase, 10 mM Tris-HCl, pH 8.5; 50 mM KCl; 1.5 mM 
MgCl
2
; and 200 mM of each dNTP. Each amplifi cation run 
contained two negative controls (ultra pure water and a 
negative DNA for toxoplasmosis) and one positive (DNA 
extracted from RH strain). After thermal cycles, PCR prod-
ucts were electrophoresed in 2% agarose gel and stained 
with GelRed (Biotium). DNA fragments were visualized 
under UV illumination. The images were analyzed by a 
Mini Bis Gel Imager and Documentation (BioSystemati-
ca). The size of fragments was based on comparison with 
a 100-bp ladder.
Marker selection
We chose two markers from the B1 gene, since it is a 35-fold 
repetitive gene with 2214 nucleotides in each repeat and is 
highly conserved among Toxoplasma strains.15,16 The first was 
B22-B23 (5’AACGGGCGAGTAGCACCTGAGGAGA3’ 
and 5’TGGGTCTACGTCGATGGCATGACAAC3’) which 
amplified a 115-bp sequence from a specific repetitive 
region as target. The amplifications were made by one 
initial denaturation cycle for 5 min at 95 °C, 35 cycles of 
denaturation at 95 °C for 1 min, annealing at 62 °C for 1 
min, and extension at 72 °C for 1 min. The procedure was 
completed by a final cycle extension for 5 min. The sec-
ond was Tg1-Tg2 (5’AAAAATGTGGGAATGAAAGAG3’ 
and 5’ACGAATCAACGGAACTGTAAT3’), which ampli-
fied a 469-bp DNA fragment of the gene as target.25 The 
PCR products were amplified by one initial denatura-
tion cycle for 5 min at 94 °C, 35 cycles of denaturation at 
94 °C for 45 sec, annealing at 50 °C for 30 sec, and exten-
sion at 72 °C for 60 sec. The procedure was completed by 
a final cycle extension for 7 min. The third marker, Tox4-
Tox5 (5’CGCTGCAGGGAGGAAGACGAAAGTTG3’ and 
5’CGCTGCAGACACAGTGCATCTGGATT3’), amplified 
a non-coding 529 bp fragment that is repeated 200-300-
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fold in the genome of T. gondii.14 The reaction conditions 
were as follows: one initial denaturation cycle for 5 min 
at 94 °C, 35 cycles of denaturation at 94 °C for 45 sec, an-
nealing at 55 °C for 45 sec, and extension at 72 °C for 45 sec. 
The procedure was completed by a final cycle extension 
for 5 min. To control the course of extraction and check 
for PCR inhibitors, all samples were assayed using mark-
er β1-β2 (5’ACCACCAACTTCATCCACGTTCACC3’ 
and 5’CTTCTGACACAACTGTGTTCACTAGC3’)26 that 
amplifi ed a 140 bp fragment of the human β-globulin gene. 
The reactions using the human marker were run simultane-
ously with the same temperature protocol for the B22-B23 
marker and in the same PCR machine.
As an illustration, Figure 1 shows the amplifi ed PCR 
products of all markers used in this study. 
Data analysis 
All divergent results were repeated at least twice. Sensitiv-
ity was calculated as a ratio of true positives/true positives + 
false negatives x 100; and specifi city, as a ratio of true nega-
tives/true negatives + false positives x 100. The percents of 
Figure 1: Amplified PCR products in two different target regions of T. gondii B1 gene: B22-B23, 115 bp (A) and Tg1-Tg2, 469 
bp (B). The third marker, Tox4-Tox5, 529 bp (C) is a non-coding fragment in the genome of T. gondii. b1-b2 marker was used as 
PCR control and amplified a 140-bp fragment of human β-globulin gene (D). The DNA fragments were resolved in 2% agarose 
gels stained with GelRed. Lane 1, 100-bp ladder; lane 2, negative control (water); lane 3, DNA from a negative; and line 4, a 
positive patient for toxoplasmosis.
concordant index (between the three markers) were calcu-
lated as the following ratio: (number of concordant results)/
(total number of samples) x 100.
RESULTS 
The marker sensitivities were analyzed using DNA extracted 
from the blood of 66 AIDS patients with cerebral toxoplas-
mosis. B22-B23, Tg1-Tg2, and Tox4-Tox5 markers ampli-
fi ed PCR products of 63, 62, and 58 samples, providing 
sensitivities of 95.5%, 93.9%, and 89.3% respectively. The 
association of at least two markers increased PCR sensitivity 
and specifi city. All positive samples had amplifi ed products 
when we analyzed the results of at least one marker (B22-
B23/Tg1-Tg2/Tox4-Tox5). The analysis in the DNA samples 
of the 36 AIDS patients with other neurologic opportunistic 
infections and without toxoplasmosis provided the specifi -
cities of 97.2%, 88.9%, and 91.7% for the markers B22-B23, 
Tg1-Tg2, and Tox4-Tox5 respectively. 
The concordance index among the markers was also 
studied. As shown in Table 1, the overall concordance of the 
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results among the three markers was of 79.4%. The concord-
ance between B22-B23 and Tox4-Tox5 were of 83.3%; be-
tween B22-B23 and Tg1-Tg2, were of 93.1%; and Tox4-Tox5 
and Tg1-Tg2, of 87.2%.
The high sensitivity and specifi city of this primer pair were 
previously reported compared to other T. gondii sequence 
primers.27 In addition, our group also showed its high sen-
sitivity and specifi city in cerebrospinal ﬂ uid and blood 
samples collected from AIDS patients and newborns.12,13,24 
Tg1-Tg2 marker25 also amplifi es a different region of the 
B1 gene in a 469 bp PCR fragment. The third marker, Tox4-
Tox5, which amplifi es a non-coding 529 bp DNA fragment, 
was selected because the target region occurs in more cop-
ies than the B1 gene that is 35-fold in the genome. 
The sensitivity, accuracy and specifi city of a diagnos-
tic test depend on optimal working conditions. In order to 
improve the PCR sensitivity, the blood samples were proc-
essed rapidly, within 48 hours of collection, to prevent Taq 
polymerase inhibition. Many components found in bio-
logical samples (blood, urine, feces, cerebrospinal liquid) 
inhibit taq-polymerase, modifying PCR results.31 
The plasma removal and erythrocyte lysis with a spe-
cifi c buffer were procedures employed before lysis of cells 
with nucleus for DNA extraction, in order to prevent PCR 
inhibitors. Furthermore, the quality of the DNA extraction 
was evaluated by β1-β2 marker that amplifi ed a PCR frag-
ment of human β-globulin gene. Positive amplifi cations 
showed that no substance present in DNA samples inhib-
ited the reaction. All blood samples tested were collected 
before or until the fi rst three days of the specifi c therapy.13 
Previous studies reported that anti-toxoplasmic therapy 
decreases diagnostic sensitivity, especially if samples were 
collected after the fi rst week of treatment.23,32 Finally, all 
divergent results between the three markers were repeated 
at least twice. Additionally, no amplifi ed PCR product was 
observed in the negative samples, showing a high specifi -
city for the three markers studied (88.9% to 97.2%).
With respect to the sensitivities, although Tox4-Tox5 tar-
gets a region repeated 200-300-fold in the genome, and the 
B1 gene is a 35-copy gene, the sensitivities of both mark-
ers from B1 gene (B22-B23 and Tg1-Tg2) were of 93.9% to 
95.9%, while the sensitivity of the Tox4-Tox5 was of 89.3%. 
These data are consistent with a recent Brazilian study con-
ducted by Okay et al.21 In addition, previous studies have 
also shown high sensitivity and specifi city for markers de-
signed to amplify different regions of the B1 gene in clinical 
samples.13,18,19,25,27,29 Other studies conducted using Europe-
an clinical samples aiming to compare sensitivities of both 
DNA regions have shown that those from repeat regions 
were more sensitive than those from the B1 gene.14,20,28,30 
The concordance index between two markers varied 
from 83.3% to 93.1%. These data demonstrated that all 
markers evaluated here were highly sensitive for T. gon-
dii detection, although B22-B23 has been shown to be the 
best. The association of two markers increases the PCR 
sensitivity, but the procedure was more expensive and 
time-consuming.
DISCUSSION
Despite that, presently, cerebral toxoplasmosis has declined 
in AIDS patients, its occurrence still represents a determi-
nant of poor diagnosis in the natural history of HIV-infect-
ed patients, even in the HAART era.9 Consequently, cerebral 
toxoplasmosis has caused high morbidity and mortality, 
particularly among Brazilian AIDS patients.10 Consequently, 
it is necessary to evaluate accurate, less invasive, and rapid 
diagnostic tools. Even though, the use of PCR has improved 
the diagnosis, some diffi culties still remain in laboratorial 
practice. Some clinical samples have small amplifi ed PCR 
products and false readings in the agarose gels due to very 
low parasite levels.
Different studies have shown that molecular markers 
that target the B1 gene or the repeated region of the T. gon-
dii genome present good sensitivity for clinical samples. 
However, these studies were conducted by using clinical 
samples collected from patients living and probably infect-
ed in Europe.17,19,20,25,27-30 Here, we chose three previously 
described markers widely used for T. gondii detection, in 
order to determine whether the results are similar in Bra-
zilian clinical samples. Two markers were based on the B1 
gene as the target region, because it is a 35-fold repetitive 
gene, highly conserved among Toxoplasma strains. The 
B22-B23 marker was able to amplify and detect the DNA 
of a single organism directly from a crude cell lysate or 10 
parasites in the presence of 100,000 human leukocytes.15,16 
Table 1. Concordance index between the three mark-
ers for the detection of T. gondii in blood samples 
  Cerebral toxoplasmosis
 PCR markers Concordant1 Discordant2 Concordance 
    index3 (%)
 B22-B23/Tg1-Tg2/
 Tox4-Tox5 81  21 (79.4)
 B22-B23/Tox4-Tox5 85 17 (83.3)
 B22-B23/Tg1-Tg2 95 07 (93.1)
 Tox4-Tox5/Tg1-Tg2 89 13 (87.2)
1Positive in all markers; 
2Negative in at least one marker; 
3Percents of concordant index were calculated as the ratio: 
(number of concordant results)/( total number of samples) 
x 100. 
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